Prognostic Role of Matrix Metalloproteinases 2, 7, 8, 9 and Their Type 1 Tissue Inhibitor in Blood Serum of Patients with Kidney Cancerстатья
Информация о цитировании статьи получена из
Web of Science ,
Scopus
Статья опубликована в журнале из списка Web of Science и/или Scopus
Дата последнего поиска статьи во внешних источниках: 23 сентября 2021 г.
Авторы:
Kushlinskii N.E. ,
Gershtein E.S. ,
Alferov A.A. ,
Bezhanova S.D. ,
Mushtenko V.V. ,
Pushkar D.Y. ,
Matveev V.B. ,
Stilidi I.S.
Журнал:
Bulletin of Experimental Biology and Medicine
Том:
168
Номер:
5
Год издания:
2020
Издательство:
Springer Nature
Местоположение издательства:
Switzerland
Первая страница:
673
Последняя страница:
676
DOI:
10.1007/s10517-020-04778-w
Аннотация:
The study compared the levels of MMP-2,7,8,9, and TIMP-1 in blood serum of healthy people (N=97) and patients with primary renal cell carcinoma (N=93) to assess relevance of these markers to prognosis of overall survival of these patients, which were followed-up over 1 to 45 months (median 26 months). To evaluate the survival with the Kaplan—Meier estimator, the median values of examined markers in the total group of patients were taken as the threshold levels. This estimator showed that the high levels of serum MMP-7 and MMP-8 were indicative for unfavorable prognosis in the total group of patients with renal cell cancer. Of them, the most significant marker was the level of MMP-7: at its low level (<6.3 ng/ml), a 3-year survival was 93%, whereas survival dropped down to 51% at a higher value of this marker (p<0.001). For MMP-8, the threshold level was 51 ng/ml, and the corresponding survivals were 78 and 58% (p<0.01). The level of MMP-7 was also prognostically significant for the patients with stage I kidney cancer: during a 3-year follow-up, all the patients with low MMP-7 were alive, while the 3-year survival of the patients with a high level of MMP-7 was only 72% (p=0.02). There were the declining trends for survival at high TIMP-1 and low MMP-2. In contrast, the level of MMP-9 virtually did not correlate with survival of the patients with renal cell cancer. © 2020, Springer Science+Business Media, LLC, part of Springer Nature.
Добавил в систему:
Герштейн Елена Сергеевна